LivaNova PLC (NASDAQ:LIVN) Position Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 17.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 621,959 shares of the company’s stock after buying an additional 93,311 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in LivaNova were worth $32,678,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of LIVN. Hexagon Capital Partners LLC lifted its position in shares of LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after purchasing an additional 370 shares during the last quarter. Fifth Third Bancorp lifted its position in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of LivaNova during the second quarter worth about $88,000. Central Pacific Bank Trust Division bought a new position in shares of LivaNova during the third quarter worth about $178,000. Finally, TradeLink Capital LLC bought a new position in shares of LivaNova during the second quarter worth about $208,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LIVN shares. Mizuho cut their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Robert W. Baird raised their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Stock Performance

LIVN opened at $51.62 on Wednesday. The business’s 50 day moving average is $52.29 and its 200-day moving average is $51.95. The stock has a market cap of $2.80 billion, a PE ratio of 122.90 and a beta of 0.98. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.47.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.